ESTRO 2025 - Abstract Book

S266

Brachytherapy - Gynaecology

ESTRO 2025

Use of IC/IS in patients with no/proximal/distal parametrial tumour extent, and to pelvic wall, increased in all groups, from 17%/54%/75/86% in EMBRACEI to 64%/86%/97%/100% in EMBRACEII. Increased conformity to CTV-T HR dose planning aim (>90Gy EQD2 10 ) and OAR sparing was observed in all groups in EMBRACEII. (Figure 1, proximal to pelvic wall involvement shown)